Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
131I-omburtamab
DRUG
3 trials
Sponsors
Y-mAbs Therapeutics
, Memorial Sloan Kettering Cancer Center
Conditions
CNS Metastases
Central Nervous System/Leptomeningeal Neoplasms
DIPG
Leptomeningeal Metastases
Neuroblastoma
Phase 1
131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma
Withdrawn
NCT05063357
Y-mAbs Therapeutics
DIPG
Start: 2022-03-31
End: 2026-12-31
Updated: 2023-06-26
Phase 2
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Terminated
NCT03275402
Y-mAbs Therapeutics
CNS Metastases, Leptomeningeal Metastases, Neuroblastoma
Start: 2018-12-11
End: 2023-06-02
Updated: 2024-02-13
Unknown Phase
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
NCT05064306
Memorial Sloan Kettering Cancer Center
Central Nervous System/Leptomeningeal Neoplasms
Updated: 2025-08-01
Related Papers
Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with <sup>131</sup>I-omburtamab for leptomeningeal disease.
2024-07-31
1 citations
LBA3 Compartmental radioimmunotherapy (cRIT) 131I-OMBURTAMAB in patients with neuroblastoma (NB) central nervous system (CNS) and/or leptomeningeal (LM) metastases: Updated results from pivotal Trial 101
Immuno-Oncology Technology
2022-12-01
3 citations
Antibodies to watch in 2020.
2020-01-01
328 citations
Finding a Cure for Children With CNS Neuroblastoma
Oncology Times
2019-07-11